AARD SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026

Faruqi & Faruqi is investigating potential securities-law claims against Aardvark Therapeutics (NASDAQ: AARD) and notes that a federal class action has been filed. Investors who purchased shares in or traceable to Aardvark's February 13, 2025 IPO, or held securities during February 13, 2025 through May 14, 2026, have until October 13, 2026 to seek lead-plaintiff status. The notice signals litigation risk but provides no details on the alleged misconduct, damages, or financial impact.

Analysis

This is primarily an incremental technical overhang rather than a fundamental datapoint: plaintiff-firm outreach does not independently establish liability, damages, or a change in Aardvark's operating outlook. For a likely low-float biotechnology issuer, however, litigation headlines can widen bid-ask spreads, raise borrow costs, and reduce marginal institutional demand until the underlying allegations and insurance coverage are clearer.

Over the next days to 1-3 months, the relevant catalyst is not the October lead-plaintiff deadline but whether the complaint survives dismissal and whether management discloses a reserve, insurance recovery limitation, financing need, or revised clinical/regulatory guidance. The more consequential second-order risk is capital access: if litigation coincides with weak trial execution or a compressed biotech financing window, AARD may need to raise equity at a larger discount, creating dilution pressure disproportionate to direct legal costs.

Consensus can overreact to the reputational signal while underweighting the procedural reality that many securities suits are dismissed or settled within D&O insurance limits. There is no clean directional trade based solely on this notice; the actionable edge is to monitor whether litigation becomes linked to a previously undisclosed clinical, safety, commercialization, or offering-document issue that changes probability-adjusted asset value.

Key Decisions for Investors

• Do not initiate a standalone AARD short solely on this notice; reassess only if the complaint identifies a verifiable operational disclosure failure or AARD breaks below post-news support on sustained volume, with borrow availability and cost confirmed first.
• For existing AARD longs, reduce gross exposure or buy 1-3 month downside protection only if implied volatility remains below the stock's realized event volatility; litigation-specific downside is otherwise likely already expensive to hedge.
• Set an alert for the first company response, court docket updates, and any financing registration/ATM filing during the next 90 days. A financing announcement combined with litigation escalation would be the strongest bearish setup because dilution and legal uncertainty reinforce each other.
• Treat a successful motion to dismiss, explicit confirmation of adequate D&O coverage, or unchanged clinical/regulatory guidance as thesis falsifiers for a bearish technical view; absent those disclosures, maintain neutral positioning rather than forcing a trade.